PT-141, Vyleesi and sexual-performance claims
The US label for Vyleesi, a bremelanotide medicine, says it is not indicated to enhance sexual performance. This does not establish a clinical indication for the supplier's PT-141 10mg Pen. Vyleesi's indication is restricted to premenopausal women with acquired, generalized hypoactive sexual desire disorder, under the label's diagnostic conditions. Vyleesi prescribing information.
A restricted disorder-related indication does not establish a general performance benefit, and it does not supply an indication for this catalogue pen. Vyleesi prescribing information.
PT-141 and bremelanotide
NLM's terminology record lists PT-141 as an entry term for bremelanotide. That connection helps identify the subject of a reference, while Vyleesi is a specifically labeled bremelanotide medicine. A terminology record does not verify the pen's contents, formulation or equivalence to that medicine. NLM bremelanotide terminology record, Vyleesi prescribing information.
The catalogue's 10mg describes the pen's listed amount. It is not a concentration or an administration instruction. The separate PT-141 vial uses a 10MG amount in its own presentation name; shared amount wording does not establish matching performance.
Bremelanotide side effects and cardiovascular warnings
The Vyleesi label contraindicates use with uncontrolled hypertension or known cardiovascular disease. It warns about transient blood-pressure increases and heart-rate reductions. Vyleesi prescribing information.
Nausea appears among the medicine's most common adverse reactions. That is a product-specific label finding, rather than a measured reaction rate for the supplier pen. Together, the restriction and adverse-reaction information describe Vyleesi's clinical scope without authenticating an item carrying the PT-141 name. Vyleesi prescribing information.
